Literature DB >> 22531230

High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients.

Anne Vincent-Salomon1, David Hajage, Alexandre Rouquette, Aurélie Cédenot, Nadège Gruel, Séverine Alran, Xavier Sastre-Garau, Brigitte Sigal-Zafrani, Alain Fourquet, Youlia Kirova.   

Abstract

BACKGROUND: The clinical management of lobular carcinoma in situ lesions remains challenging. Our aim was to evaluate the risk of relapse for lobular carcinoma in situ (LCIS) patients, diagnosed on mammography performed for microcalcifications and according to proliferation assessed by Ki67 staining.
METHODS: A series of 47 patient's files with LCIS and followed in our institution were retrospectively selected. All patients underwent lumpectomy without radiation therapy. The expression of E-cadherin, estrogen receptor (ER), progesterone receptor (PR), EGFR and Ki67 were determined. Four different classes were then defined with the following criteria: ER+ and Ki67 ≤ 10%; ER+, Ki67 >10%; ER-; ER-PR- and EGFR+.
RESULTS: Patient's mean age was 51.3 yrs. The majority of the lesions were classical LCIS (97%). All cases were E-cadherin either negative (71%) or weak and incomplete (29%). Among the 44 evaluable cases, 34 cases were ER or PR positive with KI67 ≤ 10% (79%), 9 cases ER positive with KI67 > 10% (21%), 1 case was ER and PR negative and expressed EGFR. At five years, all patients were alive, 1/34 ER positive and Ki67 low experienced a relapse contrasting with 3 out of 9 ER positive and Ki67 high (3 invasive carcinomas including 2 ductal and 1 lobular) (p = 0.0054).
CONCLUSION: In this retrospective study, we observed a higher risk of relapse associated with a high proliferative activity of classical LCIS. If confirmed in larger series, this observation suggests that radiation therapy or hormonotherapy could be discussed for patients with Ki67 high classical LCIS in order to decrease their risk of relapse.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22531230     DOI: 10.1016/j.breast.2012.03.005

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  7 in total

1.  Deficiency of CCAAT/enhancer binding protein family DNA binding prevents malignant conversion of adenoma to carcinoma in NNK-induced lung carcinogenesis in the mouse.

Authors:  Shioko Kimura; Jorge Paiz; Mitsuhiro Yoneda; Taketomo Kido; Charles Vinson; Jerrold M Ward
Journal:  Mol Cancer       Date:  2012-12-12       Impact factor: 27.401

2.  Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases.

Authors:  Bruno Cutuli; Brigitte De Lafontan; Youlia Kirova; Hugues Auvray; Agnes Tallet; Sandrine Avigdor; Claire Brunaud; Catherine Delva
Journal:  Radiat Oncol       Date:  2015-05-06       Impact factor: 3.481

3.  Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.

Authors:  Hilda Wong; Silvia Lau; Polly Cheung; Ting Ting Wong; Andrew Parker; Thomas Yau; Richard J Epstein
Journal:  BMC Cancer       Date:  2014-11-10       Impact factor: 4.430

Review 4.  Molecular drivers of lobular carcinoma in situ.

Authors:  Greg J Logan; David J Dabbs; Peter C Lucas; Rachel C Jankowitz; Daniel D Brown; Beth Z Clark; Steffi Oesterreich; Priscilla F McAuliffe
Journal:  Breast Cancer Res       Date:  2015-06-04       Impact factor: 6.466

5.  The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.

Authors:  Satbir Singh Thakur; Haocheng Li; Angela M Y Chan; Roxana Tudor; Gilbert Bigras; Don Morris; Emeka K Enwere; Hua Yang
Journal:  PLoS One       Date:  2018-01-05       Impact factor: 3.240

6.  Risk of second breast cancers after lobular carcinoma in situ according to hormone receptor status.

Authors:  Kai Mao; Yaping Yang; Wei Wu; Shi Liang; Heran Deng; Jieqiong Liu
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

7.  PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.

Authors:  Vandna Shah; Salpie Nowinski; Dina Levi; Irek Shinomiya; Narda Kebaier Ep Chaabouni; Cheryl Gillett; Anita Grigoriadis; Trevor A Graham; Rebecca Roylance; Michael A Simpson; Sarah E Pinder; Elinor J Sawyer
Journal:  Breast Cancer Res       Date:  2017-01-17       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.